BioSpace News Archive

Scenic Biotech announced that it has entered into a research collaboration with Bristol Myers Squibb to accelerate the development of Bristol Myers Squibb’s drug targets by identifying target biology for indication selection and expansion.

Iovance Biotherapeutics, Inc., a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer, announced that senior leadership plans to present at the following conferences.

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced that it will present at the Bank of America Securities Healthcare Conference in Las Vegas, NV on Tuesday, May 14, 2024, at 11:20 AM PT.

Aurinia Pharmaceuticals Inc. announced that the FDA has approved a label update for LUPKYNIS. The updated label no longer includes language indicating that the safety and efficacy of LUPKYNIS has not been established beyond one year.

Sandoz announced that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting, including the Annual Financial Statements and Consolidated Financial Statements as well as the report on non-financial matters for the 2023 financial year.

Alzheon, Inc. announced the dosing of the first patient in a long-term extension of the ongoing pivotal APOLLOE4 Phase 3 trial of 265 mg oral tablet of ALZ-801/valiltramiprosate, administered twice daily, in Early AD subjects carrying two copies of the ε4 allele of the apolipoprotein E gene.

Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the BofA Securities 2024 Health Care Conference at the Encore Hotel in Las Vegas, Nevada, on Tuesday, May 14, 2024, at 2:20 p.m. (PT).

GE HealthCare, a leading global precision care innovator, reported financial results for the first quarter ended March 31, 2024.

3M reported first-quarter results and initiated its 2024 financial earnings outlook reflecting Solventum as a discontinued operation for the full-year, including Q1.

Immunic, Inc. announced that data from its phase 2 EMPhASIS trial of lead asset, vidofludimus calcium, in patients with relapsing-remitting multiple sclerosis has been published online on April 25, 2024 in Neurology® Neuroimmunology & Neuroinflammation, an official journal of the American Academy of Neurology.